Gandhi to Lead Lilly Oncology Immuno-Oncology Medical Development

Leena Gandhi

Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now

This audio file is brought to you by

0:00

0:00

Loading audio file, please wait.

Speed
1.00

• 0.25
• 0.50
• 0.75
• 1.00
• 1.25
• 1.50
• 1.75
• 2.00

Eli Lilly and Co. has announced Leena Gandhi will join Lilly Oncology June 25 to lead immuno-oncology medical development. She is currently director of thoracic medical oncology and an associate professor of medicine at the New York University School of Medicine. Gandhi will lead a team of scientists that oversees the Lilly Oncology immunotherapy portfolio.

Gandhi graduated from the NYU School of Medicine and completed her fellowship at Dana-Farber Cancer Institute. She worked in the Early Drug Development Center at DFCI and in the Thoracic Oncology Program as head of clinical trials until 2016, at which point she joined NYU Perlmutter Cancer Center as director of thoracic medical oncology. Gandhi has worked on Phase 1, 2 and 3 trials of novel targeted therapies and immunotherapies in lung cancer, with a focus on evaluating potential biomarkers of response. She has been a lead investigator in clinical trials that helped define the use of PD-L1 as a biomarker of response to PD-1 inhibition in non-small cell lung cancer. Gandhi most recently served as lead investigator on the KEYNOTE-189 study, published in the New England Journal of Medicine in April 2018. This study demonstrated an improved survival rate with the addition of pembrolizumab to pemetrexed and platinum chemotherapy for patients with recurrent lung cancer.